BR0211565A - Derivados de diamina - Google Patents
Derivados de diaminaInfo
- Publication number
- BR0211565A BR0211565A BR0211565-4A BR0211565A BR0211565A BR 0211565 A BR0211565 A BR 0211565A BR 0211565 A BR0211565 A BR 0211565A BR 0211565 A BR0211565 A BR 0211565A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- optionally substituted
- dialkyl
- alkoxy
- alkylene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
"DERIVADOS DE DIAMINA". Descreve-se compostos representados pela fórmula genérica (1), seus sais, seus solvatos, ou seus N-óxidos: Q^ 1^ -Q^ 2^ -T^ 0^ -N (R^ 1^) -Q^ 3^-N (R^ 2^)-T^ 1^ -Q^ 4^ (1) onde R^ 1^ e R^ 2^ representam, cada um, hidrogênio, etc. Q^ 1^ representa hidrocarbila com 5 ou 6 membros, saturada ou insaturada, opcionalmente substituída, etc.; Q^ 2^ representa uma ligação simples, etc.; Q^ 3^ representa o seguinte grupo: onde é Q^ 5^ representa alquileno de C~ 1-8~, etc. ; e T^ 0^ e T^ 1^ representam, cada um, carbonila, etc. Estes compostos são úteis como preventivos e/ou medicamentos para infarto cerebral, embolia cerebral, infarto do miocárdio, angina, infarto pulmonar, embolia pulmonar, doença de Buerger, trombose venosa profunda, coagulação intravascular disseminada, trombose após substituição por válvula ou articulação artificial, trombose e reoclusão após reconstrução circulatória, síndrome da resposta inflamatória sistêmica (SIRS), disfunção de múltiplos órgãos (MODS), trombose em circulação extracorpórea, ou coagulação sang³ínea após coleta de sangue.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001243046 | 2001-08-09 | ||
JP2001311808 | 2001-10-09 | ||
JP2001398708 | 2001-12-28 | ||
PCT/JP2002/002683 WO2003000657A1 (fr) | 2001-06-20 | 2002-03-20 | Derives de diamine |
PCT/JP2002/006141 WO2003000680A1 (fr) | 2001-06-20 | 2002-06-20 | Derives de diamine |
PCT/JP2002/008119 WO2003016302A1 (fr) | 2001-08-09 | 2002-08-08 | Derives de diamine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0211565A true BR0211565A (pt) | 2004-06-29 |
Family
ID=32600712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0211565-4A BR0211565A (pt) | 2001-08-09 | 2002-08-08 | Derivados de diamina |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1415992B1 (pt) |
JP (1) | JP4331595B2 (pt) |
KR (1) | KR100908966B1 (pt) |
CN (1) | CN100545160C (pt) |
AT (1) | ATE556066T1 (pt) |
AU (1) | AU2002328596B2 (pt) |
BR (1) | BR0211565A (pt) |
CA (1) | CA2456841A1 (pt) |
ES (1) | ES2383749T3 (pt) |
HK (1) | HK1095814A1 (pt) |
IL (2) | IL160204A0 (pt) |
MX (1) | MXPA04001272A (pt) |
NO (1) | NO327003B1 (pt) |
PL (1) | PL368402A1 (pt) |
RU (1) | RU2314303C2 (pt) |
WO (1) | WO2003016302A1 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI290136B (en) | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
WO2003000657A1 (fr) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de diamine |
WO2003000680A1 (fr) * | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de diamine |
CA2511493A1 (en) * | 2002-12-25 | 2004-07-15 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
US7291615B2 (en) | 2003-05-01 | 2007-11-06 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
KR101215213B1 (ko) | 2003-11-12 | 2012-12-24 | 다이이찌 산쿄 가부시키가이샤 | 티아졸 유도체의 제조법 |
NZ548212A (en) | 2003-12-29 | 2010-07-30 | Sepracor Inc | Pyrrole and pyrazole DAAO inhibitors |
HUE029336T2 (en) | 2005-09-16 | 2017-02-28 | Daiichi Sankyo Co Ltd | For the preparation of an optically active diamine derivative and process |
JP5432526B2 (ja) | 2006-01-06 | 2014-03-05 | サノビオン ファーマシューティカルズ インク | モノアミン再取り込み阻害剤としてのシクロアルキルアミン |
KR101381768B1 (ko) | 2006-01-06 | 2014-04-07 | 선오비온 파마슈티컬스 인코포레이티드 | 테트랄론-기재 모노아민 재흡수 저해제 |
AU2007233041B2 (en) | 2006-03-31 | 2013-05-02 | Sepracor Inc. | Preparation of chiral amides and amines |
US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
EP2062878A4 (en) | 2006-08-30 | 2010-09-08 | Shionogi & Co | HYDRAZINE AMIDE DERIVATIVE |
US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
CN101652139A (zh) | 2007-03-29 | 2010-02-17 | 第一三共株式会社 | 药物组合物 |
NZ580429A (en) | 2007-05-31 | 2012-04-27 | Sepracor Inc | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
JP5683273B2 (ja) | 2008-12-12 | 2015-03-11 | 第一三共株式会社 | 光学活性カルボン酸の製造方法 |
EP2371830B1 (en) * | 2008-12-17 | 2013-10-02 | Daiichi Sankyo Company, Limited | Method for producing diamine derivative |
JPWO2010082531A1 (ja) | 2009-01-13 | 2012-07-05 | 第一三共株式会社 | 活性化血液凝固因子阻害剤 |
JP5666424B2 (ja) | 2009-03-10 | 2015-02-12 | 第一三共株式会社 | ジアミン誘導体の製造方法 |
JP5652879B2 (ja) | 2009-03-13 | 2015-01-14 | 第一三共株式会社 | 光学活性なジアミン誘導体の製造方法 |
WO2010131663A1 (ja) * | 2009-05-15 | 2010-11-18 | 第一三共株式会社 | オキサミド誘導体 |
KR20120037396A (ko) | 2009-06-18 | 2012-04-19 | 다이이찌 산쿄 가부시키가이샤 | 용출성이 개선된 의약 조성물 |
WO2011059080A1 (ja) * | 2009-11-16 | 2011-05-19 | 第一三共株式会社 | 同位体置換されたジアミン誘導体 |
ES2706880T3 (es) | 2010-02-22 | 2019-04-01 | Daiichi Sankyo Co Ltd | Preparación sólida de liberación sostenida para uso oral |
WO2011102505A1 (ja) | 2010-02-22 | 2011-08-25 | 第一三共株式会社 | 経口用徐放性固形製剤 |
WO2011102506A1 (ja) | 2010-02-22 | 2011-08-25 | 第一三共株式会社 | 経口用徐放性固形製剤 |
CA2793413C (en) * | 2010-03-19 | 2015-11-24 | Daiichi Sankyo Company, Limited | Crystal form of edoxaban tosylate monohydrate and method of producing same |
ES2601884T3 (es) | 2010-03-19 | 2017-02-16 | Daiichi Sankyo Company, Limited | Procedimiento para mejorar la capacidad de disolución de un anticoagulante |
WO2011149110A1 (en) | 2010-05-28 | 2011-12-01 | Daiichi Sankyo Company, Limited | Novel composition for the prevention and/or treatment of thromboembolism |
WO2012002538A1 (ja) | 2010-07-02 | 2012-01-05 | 第一三共株式会社 | 光学活性ジアミン誘導体の塩の製造方法 |
HUE035506T2 (en) | 2010-08-04 | 2018-05-02 | Daiichi Sankyo Co Ltd | Process for Preparing a Compound with a New Sandmeyer-Type Reaction Using a Nitric Dioxide Compound as a Reaction Catalyst |
WO2013022059A1 (ja) | 2011-08-10 | 2013-02-14 | 第一三共株式会社 | ジアミン誘導体含有医薬組成物 |
BR112015004190A2 (pt) | 2012-09-03 | 2017-07-04 | Daiichi Sankyo Co Ltd | composição farmacêutica de liberação sustentada, e, método para produzir uma composição farmacêutica de liberação sustentada |
CN104936961B (zh) | 2013-03-29 | 2016-10-26 | 第一三共株式会社 | (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法 |
TWI602803B (zh) | 2013-03-29 | 2017-10-21 | 第一三共股份有限公司 | 光學活性二胺衍生物之製造方法 |
HUE052100T2 (hu) * | 2014-02-18 | 2021-04-28 | Daiichi Sankyo Co Ltd | Eljárás aktivált véralvadási faktor X (FXA) inhibitorának alõállítására |
JP2017210468A (ja) * | 2016-05-23 | 2017-11-30 | 宇部興産株式会社 | ヨードラクトン化合物の製造方法 |
JP6696474B2 (ja) * | 2016-06-24 | 2020-05-20 | 宇部興産株式会社 | オキサビシクロオクタン化合物の製造方法 |
CN106467475A (zh) * | 2016-08-29 | 2017-03-01 | 上海大学 | 邻位双叠氮化合物的制备方法 |
CN107573256B (zh) * | 2017-09-26 | 2020-02-21 | 安徽国星生物化学有限公司 | 一种对氯苯肼盐酸盐连续化生产方法及其装置 |
CN111138357B (zh) * | 2018-11-06 | 2022-11-04 | 天津药物研究院有限公司 | 2-氧代-1,2-二氢喹啉类衍生物、其制备方法及其在医药上的应用 |
CN111606827B (zh) * | 2020-06-23 | 2022-10-25 | 内蒙古京东药业有限公司 | 一种制备依度沙班手性胺中间体的方法 |
CN111763222B (zh) * | 2020-08-03 | 2021-05-25 | 珠海市海瑞德新材料科技有限公司 | 用于制备依度沙班游离碱的中间体及其制备方法和应用 |
WO2022129535A1 (en) | 2020-12-18 | 2022-06-23 | Krka, D.D., Novo Mesto | Edoxaban formulation containing no sugar alcohols |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986007257A2 (en) * | 1985-06-07 | 1986-12-18 | The Upjohn Company | Antiarrhythmic use for aminocycloalkylamides |
WO1992004017A1 (en) * | 1990-09-10 | 1992-03-19 | The Upjohn Company | Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants |
US5430150A (en) * | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
AU6252794A (en) * | 1993-03-03 | 1994-09-26 | Eli Lilly And Company | Balanoids |
DE19536783A1 (de) | 1995-09-21 | 1997-03-27 | Diagnostikforschung Inst | Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope |
US6274715B1 (en) | 1995-11-08 | 2001-08-14 | Abbott Laboratories | Tricyclic erythromycin derivatives |
IT1291823B1 (it) * | 1997-04-08 | 1999-01-21 | Menarini Ricerche Spa | Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche |
US6207679B1 (en) * | 1997-06-19 | 2001-03-27 | Sepracor, Inc. | Antimicrobial agents uses and compositions related thereto |
US6130349A (en) | 1997-12-19 | 2000-10-10 | The Board Of Trustees Of The Leland Stanford Junior University | Catalytic compositions and methods for asymmetric allylic alkylation |
GB9807104D0 (en) * | 1998-04-02 | 1998-06-03 | Chirotech Technology Ltd | The preparation of phosphine ligands |
DE19814801A1 (de) * | 1998-04-02 | 1999-10-07 | Basf Ag | Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen |
AU767409B2 (en) * | 1998-04-21 | 2003-11-06 | Du Pont Pharmaceuticals Company | 5-aminoindeno(1,2-C)pyrazol-4-ones as anti-cancer and anti-proliferative agents |
EP1090016B1 (en) * | 1998-06-30 | 2002-10-30 | Chirotech Technology Limited | The preparation of arylphosphines |
TW434207B (en) * | 1998-07-24 | 2001-05-16 | Everlight Chem Ind Corp | Chiral ligand and method for preparing cyanohydrins from aldehydes |
WO2000009480A1 (fr) * | 1998-08-11 | 2000-02-24 | Daiichi Pharmaceutical Co., Ltd. | Nouveaux derives sulfonyle |
AU2241400A (en) * | 1999-04-06 | 2000-10-12 | Yamanouchi Pharmaceutical Co., Ltd. | Novel thiazolobenzoimidazole derivative |
GB9909592D0 (en) * | 1999-04-26 | 1999-06-23 | Chirotech Technology Ltd | Process for the preparation of calanolide precursors |
IL146952A0 (en) * | 1999-06-15 | 2002-08-14 | Rhodia Chimie Sa | Sulphonylamides and carboxamides and their use in asymmmetical catalysis |
US6492408B1 (en) * | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
TWI290136B (en) * | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
WO2003000680A1 (fr) * | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de diamine |
WO2003000657A1 (fr) * | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Derives de diamine |
CA2726702A1 (en) * | 2001-09-21 | 2003-04-03 | Bristol-Myers Squibb Company | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
WO2003048081A2 (en) * | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
AU2003273179A1 (en) * | 2002-05-10 | 2003-12-12 | Bristol-Myers Squibb Company | 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
-
2002
- 2002-08-08 WO PCT/JP2002/008119 patent/WO2003016302A1/ja active Application Filing
- 2002-08-08 BR BR0211565-4A patent/BR0211565A/pt not_active IP Right Cessation
- 2002-08-08 IL IL16020402A patent/IL160204A0/xx unknown
- 2002-08-08 RU RU2004106625/04A patent/RU2314303C2/ru not_active IP Right Cessation
- 2002-08-08 AT AT02762760T patent/ATE556066T1/de active
- 2002-08-08 JP JP2003521226A patent/JP4331595B2/ja not_active Expired - Lifetime
- 2002-08-08 PL PL02368402A patent/PL368402A1/xx not_active Application Discontinuation
- 2002-08-08 KR KR1020047001827A patent/KR100908966B1/ko not_active IP Right Cessation
- 2002-08-08 ES ES02762760T patent/ES2383749T3/es not_active Expired - Lifetime
- 2002-08-08 AU AU2002328596A patent/AU2002328596B2/en not_active Ceased
- 2002-08-08 CA CA002456841A patent/CA2456841A1/en not_active Abandoned
- 2002-08-08 MX MXPA04001272A patent/MXPA04001272A/es active IP Right Grant
- 2002-08-08 EP EP02762760A patent/EP1415992B1/en not_active Expired - Lifetime
- 2002-08-08 CN CNB02819652XA patent/CN100545160C/zh not_active Expired - Fee Related
-
2004
- 2004-02-04 IL IL160204A patent/IL160204A/en not_active IP Right Cessation
- 2004-02-06 NO NO20040557A patent/NO327003B1/no not_active IP Right Cessation
-
2007
- 2007-03-19 HK HK07102898.2A patent/HK1095814A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1415992B1 (en) | 2012-05-02 |
IL160204A (en) | 2010-11-30 |
ES2383749T3 (es) | 2012-06-26 |
IL160204A0 (en) | 2004-07-25 |
NO327003B1 (no) | 2009-04-06 |
RU2004106625A (ru) | 2005-06-27 |
KR20040023720A (ko) | 2004-03-18 |
MXPA04001272A (es) | 2004-05-27 |
EP1415992A4 (en) | 2006-07-26 |
RU2314303C2 (ru) | 2008-01-10 |
PL368402A1 (en) | 2005-03-21 |
HK1095814A1 (en) | 2007-05-18 |
CN100545160C (zh) | 2009-09-30 |
CA2456841A1 (en) | 2003-02-27 |
EP1415992A1 (en) | 2004-05-06 |
AU2002328596B2 (en) | 2007-09-20 |
KR100908966B1 (ko) | 2009-07-22 |
WO2003016302A1 (fr) | 2003-02-27 |
ATE556066T1 (de) | 2012-05-15 |
NO20040557L (no) | 2004-04-02 |
CN1894238A (zh) | 2007-01-10 |
JPWO2003016302A1 (ja) | 2004-12-02 |
JP4331595B2 (ja) | 2009-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0211565A (pt) | Derivados de diamina | |
JP7269731B2 (ja) | 標的タンパク質の分解向上のための化合物および方法 | |
NZ509318A (en) | Amide derivatives, their preparation and use in the treatment of diseases mediated by cytokines | |
WO2006138265A3 (en) | Heterocyclic aspartyl protease inhibitors, preparation and use thereof | |
SG146694A1 (en) | 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo-2,3-c pyridin-2- ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes | |
TW200500362A (en) | 5-membered heteroaromatic ring compound and pharmaceutical use thereof | |
WO2006078283A3 (en) | Quinoxaline inhibitors of hedgehog signalling | |
GEP20105053B (en) | Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors | |
DE69528485T2 (de) | Biphenylderivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel | |
CA2405521A1 (en) | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties | |
MXPA01008142A (es) | Compuestos de amida, y uso medicinal de los mismos. | |
HUP0004595A2 (hu) | Aciklikus metalloproteáz inhibitorok | |
HRP20130664T1 (en) | Heterocyclic aspartyl protease inhibitors | |
DE69530683D1 (de) | Sulfonamid derivate und deren verwendung | |
WO2002044157A3 (en) | Parb inhibitors | |
DE602004031722D1 (de) | Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden | |
DK0669912T3 (da) | N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister | |
JP2003183286A5 (pt) | ||
ATE388939T1 (de) | N-((piperazinyl)hetaryl)arylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor | |
BRPI0407578A (pt) | derivados da purina, processo de preparação, sua aplicação a tìtulo de medicamentos, composições farmacêuticas e utilização | |
WO2004047738A3 (en) | Arylcyclopropylcarboxylic amides as potassium channel openers | |
MY140027A (en) | Cyclic amine derivatives, process for their preparation and pharmaceuticals containing them | |
DK1368336T3 (da) | Thiophensubstituerede aminderivater som GlyT-1-inhibitorer | |
ATE432920T1 (de) | Fluorierungsmittel und verfahren zu deren herstellung | |
AR047502A1 (es) | Dilatador modificado util para administracion de farmacos a lo largo del manguito del dilatador |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012. |